| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $17,953,158 | 37 | 100 |
| Markowitz Wayne | GM & SVP, Surgical | 0 | $0 | 2 | $70,265 | $-70,265 |
| LORANGER STEVEN R | director | 0 | $0 | 1 | $438,576 | $-438,576 |
| Chopra Daveen | CVP, TMTT | 0 | $0 | 3 | $486,228 | $-486,228 |
| STONE HEISZ LESLIE | director | 0 | $0 | 2 | $653,490 | $-653,490 |
| Lippis Daniel J. | CVP, JAPAC | 0 | $0 | 9 | $730,141 | $-730,141 |
| Wood Larry L | Global President TAVR & Surg | 0 | $0 | 2 | $1.37M | $-1.37M |
| Zovighian Bernard J | CEO | 0 | $0 | 6 | $4.35M | $-4.35M |
| Ullem Scott B. | CVP, Chief Financial Officer | 0 | $0 | 6 | $5.01M | $-5.01M |
| BOBO DONALD E JR | CVP,Strategy/Corp Development | 0 | $0 | 8 | $5.22M | $-5.22M |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Over the last 12 months, insiders at Edwards Lifesciences Corporation have bought $0 and sold $17.95M worth of Edwards Lifesciences Corporation stock.
On average, over the past 5 years, insiders at Edwards Lifesciences Corporation have bought $109,049 and sold $54.49M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 580 shares for transaction amount of $49,753 was made by Zovighian Bernard J (CEO) on 2024‑05‑06.
| 2026-01-09 | Sale | Lippis Daniel J. | CVP, TAVR | 1,019 0.0002% | $85.70 | $87,332 | -2.11% | |
| 2026-01-06 | Sale | BOBO DONALD E JR | CVP,Strategy/Corp Development | 11,340 0.002% | $85.66 | $971,429 | -2.45% | |
| 2025-12-12 | Sale | BOBO DONALD E JR | CVP,Strategy/Corp Development | 11,386.12 0.002% | $83.76 | $953,748 | +2.47% | |
| 2025-12-12 | Sale | STONE HEISZ LESLIE | director | 2,615 0.0004% | $83.41 | $218,120 | +2.47% | |
| 2025-12-12 | Sale | Lippis Daniel J. | CVP, JAPAC | 1,019 0.0002% | $84.03 | $85,625 | +2.47% | |
| 2025-12-11 | Sale | Chopra Daveen | CVP, TMTT & Surgical | 2,000 0.0003% | $84.38 | $168,750 | +0.88% | |
| 2025-12-10 | Sale | BOBO DONALD E JR | CVP,Strategy/Corp Development | 11,340 0.0019% | $83.83 | $950,581 | +1.10% | |
| 2025-12-10 | Sale | Zovighian Bernard J | CEO | 3,863 0.0007% | $83.45 | $322,367 | +1.10% | |
| 2025-12-09 | Sale | Ullem Scott B. | CVP, Chief Financial Officer | 7,700 0.0013% | $84.47 | $650,412 | +1.87% | |
| 2025-12-08 | Sale | Zovighian Bernard J | CEO | 21,487 0.0037% | $85.21 | $1.83M | +0.60% | |
| 2025-12-08 | Sale | Markowitz Wayne | CVP, JAPAC | 583 0.0001% | $86.01 | $50,144 | +0.60% | |
| 2025-11-10 | Sale | Ullem Scott B. | CVP, Chief Financial Officer | 13,000 0.0022% | $83.08 | $1.08M | +1.25% | |
| 2025-11-10 | Sale | Lippis Daniel J. | CVP, JAPAC | 1,020 0.0002% | $82.55 | $84,196 | +1.25% | |
| 2025-08-25 | Sale | Chopra Daveen | CVP, TMTT | 2,500 0.0004% | $81.95 | $204,865 | +2.70% | |
| 2025-08-18 | Sale | Wood Larry L | Global President TAVR & Surg | 8,950 0.0015% | $78.06 | $698,679 | +5.61% | |
| 2025-07-28 | Sale | Lippis Daniel J. | CVP, JAPAC | 4,114 0.0007% | $79.46 | $326,901 | +3.59% | |
| 2025-06-16 | Sale | Wood Larry L | Global President TAVR & Surg | 8,950 0.0015% | $75.23 | $673,268 | +6.79% | |
| 2025-06-03 | Sale | Zovighian Bernard J | CEO | 967 0.0002% | $77.32 | $74,772 | +1.56% | |
| 2025-06-02 | Sale | BOBO DONALD E JR | CVP,Strategy/Corp Development | 2,570 0.0004% | $77.40 | $198,911 | +0.98% | |
| 2025-05-30 | Sale | Zovighian Bernard J | CEO | 16,099 0.0027% | $77.21 | $1.24M | +0.74% |
| Wood Larry L | Global President TAVR & Surg | 206900 0.0352% | $17.45M | 0 | 102 | |
| LORANGER STEVEN R | director | 60372 0.0103% | $5.09M | 1 | 1 | <0.0001% |
| Ullem Scott B. | CVP, Chief Financial Officer | 39898 0.0068% | $3.37M | 0 | 41 | |
| Chopra Daveen | CVP, TMTT & Surgical | 32201 0.0055% | $2.72M | 0 | 20 | |
| BOBO DONALD E JR | CVP,Strategy/Corp Development | 31870 0.0054% | $2.69M | 0 | 153 | |
| STONE HEISZ LESLIE | director | 30948 0.0053% | $2.61M | 0 | 6 | |
| Lippis Daniel J. | CVP, TAVR | 22002 0.0037% | $1.86M | 0 | 15 | |
| Markowitz Wayne | CVP, JAPAC | 17563 0.003% | $1.48M | 0 | 3 | |
| Zovighian Bernard J | CEO | 8597 0.0015% | $725,119.09 | 1 | 12 | <0.0001% |
| Lemercier Jean-Luc M | CVP, EMEACLA and JAPAC | 173849 0.0296% | $14.66M | 0 | 24 | |
| Verguet Patrick B | CVP, Europe | 129137 0.022% | $10.89M | 0 | 91 | |
| KEHL JOHN H JR | CVP, Strategy & Corp Dev | 102839 0.0175% | $8.67M | 0 | 27 | |
| WANG HUIMIN | CVP, Japan & Intercontinental | 99381 0.0169% | $8.38M | 0 | 156 | |
| Cardis John T | director | 91458 0.0156% | $7.71M | 0 | 5 | |
| BOWLIN MICHAEL R | director | 81751 0.0139% | $6.9M | 0 | 10 | |
| GALLAHUE KIERAN | director | 67219 0.0114% | $5.67M | 2 | 2 | +27.32% |
| VALERIANI NICHOLAS J | director | 63811 0.0109% | $5.38M | 1 | 1 | <0.0001% |
| GARREN BRUCE P | CVP, Public Affairs/Special Co | 62748 0.0107% | $5.29M | 0 | 17 | |
| PYOTT DAVID E I | director | 48429 0.0082% | $4.08M | 1 | 6 | +10.01% |
| MCNEIL BARBARA J | director | 46454 0.0079% | $3.92M | 1 | 5 | +33.89% |
| Abate Thomas M | CVP, CFO | 44393 0.0076% | $3.74M | 0 | 23 | |
| Szyman Catherine M. | CVP, Critical Care | 34814 0.0059% | $2.94M | 1 | 56 | +31.99% |
| Solomon Carlyn D | CVP, Critical Care & Vascular | 31154 0.0053% | $2.63M | 0 | 18 | |
| INGRAM ROBERT ALEXANDER | director | 30541 0.0052% | $2.58M | 0 | 5 | |
| BESSLER ANITA | CVP | 29410 0.005% | $2.48M | 0 | 7 | |
| NEAL PHILIP M | director | 27333 0.0047% | $2.31M | 0 | 1 | |
| Marsh Martha H. | 26777 0.0046% | $2.26M | 0 | 1 | ||
| LOUCKS VERNON R JR | director | 17106 0.0029% | $1.44M | 0 | 2 | |
| FOSTER STUART L | CVP, Critical Care / Vascular | 17300 0.0029% | $1.46M | 0 | 8 | |
| Nevinny Corinne H | CVP & Pres., Global Ops | 16687 0.0028% | $1.41M | 0 | 13 | |
| SELLERS ROBERT W.A. | SVP, Corporate Controller | 13087 0.0022% | $1.1M | 0 | 18 | |
| Redmond Paul C | CVP, Global Operations | 12534 0.0021% | $1.06M | 0 | 14 | |
| Martin John Alexander | CVP, North America | 11300 0.0019% | $953,155.00 | 0 | 1 | |
| VON SCHACK WESLEY W | director | 8000 0.0014% | $674,800.00 | 3 | 6 | +20.17% |
| MUSSALLEM MICHAEL A | director | 4486 0.0008% | $378,378.92 | 0 | 239 | |
| LINK WILLIAM J PHD | director | 4722 0.0008% | $398,300.70 | 0 | 5 | |
| McCauley Christine Z | CVP, Human Resources | 4234 0.0007% | $357,137.90 | 0 | 1 | |
| WOODGRIFT RANDEL WILLIAM | Corp VP, Manufacturing Ops | 3349 0.0006% | $282,488.15 | 0 | 4 | |
| REINDL ROBERT C | CVP, H.R. and Communications | 1124 0.0002% | $94,809.40 | 0 | 23 |
| Increased Positions | 550 | +39.63% | 43M | +8.45% |
| Decreased Positions | 567 | -40.85% | 46M | -9.07% |
| New Positions | 104 | New | 6M | New |
| Sold Out Positions | 107 | Sold Out | 6M | Sold Out |
| Total Postitions | 1,371 | -1.22% | 500M | -0.62% |
| Vanguard Group Inc | $6M | 12.13% | 70.36M | +365,581 | +0.52% | 2025-09-30 |
| Blackrock, Inc. | $4.63M | 9.36% | 54.29M | -1M | -2.43% | 2025-09-30 |
| State Street Corp | $2.19M | 4.42% | 25.62M | -14,746 | -0.06% | 2025-09-30 |
| Jpmorgan Chase & Co | $2.14M | 4.32% | 25.06M | -2M | -6.41% | 2025-09-30 |
| Wellington Management Group Llp | $1.78M | 3.59% | 20.8M | +977,933 | +4.93% | 2025-09-30 |
| Bank Of New York Mellon Corp | $1.62M | 3.28% | 19.01M | +1M | +8.09% | 2025-09-30 |
| Fmr Llc | $1.24M | 2.51% | 14.58M | +12M | +476.71% | 2025-09-30 |
| Jennison Associates Llc | $1.19M | 2.41% | 13.96M | +2M | +19.6% | 2025-09-30 |
| Geode Capital Management, Llc | $1.1M | 2.21% | 12.84M | +114,729 | +0.9% | 2025-09-30 |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | $788,466.00 | 1.59% | 9.24M | +110,840 | +1.21% | 2025-09-30 |